Fever, diarrhea and vomiting are reported as very common side effects.

Based on the pharmacokinetics of the rotavirus vaccine, there are no conceivable porphyrinogenic effects.

Live human-bovine rotavirus reassortants.

The rotavirus vaccine is indicated for the active immunization of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection. It is administered orally by a 3-dose regimen given with intervals of at least 4 weeks. The first dose may be given from the age of 6 weeks and no later than 12 weeks. The third (last) dose may be given up to the age of 32 weeks, but preferably before the age of 20-22 weeks.

The rotavirus vaccine is not metabolized by the cytochrome P450 system.